Yield10 Bioscience, Inc. (YTEN)

NASDAQ: YTEN · IEX Real-Time Price · USD
0.239
+0.009 (3.87%)
At close: Apr 25, 2024, 4:00 PM
0.233
-0.006 (-2.34%)
Pre-market: Apr 26, 2024, 4:02 AM EDT
3.87%
Market Cap 3.68M
Revenue (ttm) 60,000
Net Income (ttm) -14.46M
Shares Out 15.40M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 272,215
Open 0.246
Previous Close 0.230
Day's Range 0.224 - 0.243
52-Week Range 0.180 - 3.290
Beta 1.61
Analysts Buy
Price Target 2.25 (+841.42%)
Earnings Date May 8, 2024

About YTEN

Yield10 Bioscience, Inc. operates as agricultural bioscience company in the United States. The company primarily focuses on commercializing products using the Camelina oilseeds. Its products include Camelina oil for use as a low-carbon feedstock oil for biofuels; Omega-3 oils for human nutrition; and PHA bioplastics. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts. [Read more]

Sector Materials
IPO Date Nov 10, 2006
Employees 29
Stock Exchange NASDAQ
Ticker Symbol YTEN
Full Company Profile

Financial Performance

In 2023, YTEN's revenue was $60,000, a decrease of -86.67% compared to the previous year's $450,000. Losses were -$14.46 million, 6.55% more than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for YTEN stock is "Buy." The 12-month stock price forecast is $2.25, which is an increase of 841.42% from the latest price.

Price Target
$2.25
(841.42% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market -Advanced regulatory and seed scale-up program for omega-3 Camelina -E3902 oil trait in Camelina clear...

24 days ago - GlobeNewsWire

Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024

WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report ...

4 weeks ago - GlobeNewsWire

Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada

WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported that the Plant Biosafety Offic...

4 weeks ago - GlobeNewsWire

USDA-APHIS Determines that Yield10 Bioscience's Omega-3 Camelina Varieties May Be Planted and Bred in the United States

Yield10 Bioscience achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina in the United States.

5 weeks ago - GlobeNewsWire

Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests

-Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil markets -Herbicide tolerance is critical to planting the Camelina crop on large acreage ...

2 months ago - GlobeNewsWire

Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock

Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel F...

2 months ago - GlobeNewsWire

Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program

-Prioritizes Activities to Advance Omega-3 Camelina Program in 2024 -Reports Completion of Contra Season Production of Omega-3 Camelina Seed in Chile - Company also Provides Update on Nasdaq Status - ...

2 months ago - GlobeNewsWire

Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

WOBURN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company recently file...

3 months ago - GlobeNewsWire

USDA-APHIS Determines that Yield10 Bioscience's Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States

-Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America -Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America

5 months ago - GlobeNewsWire

USDA-APHIS Determines that Yield10 Bioscience's Glufosinate Tolerant Camelina May Be Planted and Bred in the United States

-Yield10 Achieves a Significant Milestone in the Development  of Camelina as a Commercial Crop for Producing Biofuels and Omega-3 Oils

5 months ago - GlobeNewsWire

Yield10 Bioscience Announces Third Quarter 2023 Financial Results

-Establishes "Camelina Seed Genetics to Biofuel" Platform -Advances Herbicide Tolerant Camelina Varieties toward Commercialization -Exercises Option to Finalize Exclusive, Global Commercial License to...

5 months ago - GlobeNewsWire

Yield10 Bioscience to Announce Third Quarter 2023 Financial Results and Host a Conference Call on Tuesday, November 14, 2023

WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report i...

6 months ago - GlobeNewsWire

Yield10 Bioscience and BioMar Aim to Grow Fish Oil on Land

Yield10 Bioscience and BioMar Group have signed an LOI to form a long-term partnership to commercialize a Camelina crop containing enriched levels of EPA and DHA equal to fish oil. After a decade of r...

6 months ago - GlobeNewsWire

Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research

WOBURN, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has exercised...

6 months ago - GlobeNewsWire

Yield10 Bioscience Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

-On track for commercial launch of first herbicide tolerant Camelina variety as early as 2025 -First field tests of stacked herbicide tolerant winter Camelina underway -Recent positive field tests dem...

7 months ago - GlobeNewsWire

Yield10 Bioscience Completes Harvest of a Majority of the 2023 Winter and Spring Camelina Grain Grown Under Contract, Generating Revenue from Biofuel Production

Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform

7 months ago - GlobeNewsWire

Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that management will partici...

8 months ago - GlobeNewsWire

Yield10 Bioscience Announces Closing of $3.7 Million Public Offering

WOBURN, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the closing of its previously ...

9 months ago - GlobeNewsWire

Yield10 Bioscience Announces Second Quarter 2023 Financial Results

-Harvesting underway for contracted winter and spring Camelina acres for the biofuels market -Reported positive results in first field tests of stacked herbicide tolerant Camelina -Filed a request for...

9 months ago - GlobeNewsWire

Yield10 Bioscience to Announce Second Quarter 2023 Financial Results and Host a Conference Call on Monday, August 14, 2023

WOBURN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report i...

9 months ago - GlobeNewsWire

Yield10 Bioscience Announces Pricing of $3.7 Million Public Offering

WOBURN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the pricing of its public offe...

9 months ago - GlobeNewsWire

Yield10 Bioscience Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina, Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market

-Findings demonstrate a key advancement in the development of proprietary Camelina varieties tolerant to application of broadleaf weed control as well as to Group 2 soil residual herbicide chemistries

9 months ago - GlobeNewsWire

Yield10 Bioscience Files Request for Regulatory Status Review under USDA-APHIS's SECURE Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil

-Omega-3 (EPA) Camelina planted at acre-scale in US nearing maturity -Development program moving forward at a solid pace toward commercialization WOBURN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Yield...

9 months ago - GlobeNewsWire

Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BBLGFRESVTGN
11 months ago - Benzinga

Yield10 Bioscience Announces First Quarter 2023 Financial Results

WOBURN, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the first ...

1 year ago - GlobeNewsWire